Objective: To evaluate the clinical efficacy and safety of dapagliflozin combined with insulin aspart 30 in the treatment of type 2 diabetes. Methods: We collected 88 patients with type 2 diabetes who were hospitalized in the Second Hospital of Jilin university from June 2017 to December 2017, and assigned them into an observation group (n=40) and a control group (n=48). The observation group received the treatment of dapagliflozin combined with insulin aspart 30, and the control group was only treated with insulin aspart 30. In the follow-up visit, the study recorded the patient’s fasting plasma glucose (FPG), 2-hour postprandial blood glucose (2hPG), hemoglobin A1c (HbA1c), waist, BMI, insulin doses, presence of hypoglycemic events and the incidence of adverse cardiovascular events. Results: There was no significant difference in FPG, 2hPG, and HbA1c between the two groups after 3 months of treatment (P>0.05). BMI and waist in the observation group were significantly lower than before (P<0.05). The insulin dose and incidence of cardiovascular adverse events in the observation group were significantly lower than that in the control group (P<0.05), and there was no significant difference in the incidence of hypoglycemia between the 2 groups (P>0.05). Conclusion: The clinical efficacy of dapagliflozin combined with insulin aspart 30 is better than that only using insulin aspart 30 in the treatment of type 2 diabetes. It can control blood glucose stably, lose weight, and has a good safety.